Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis

Group A 1. Patients over 18 years old, 2. Breast cancer (adenocarcinoma in situ or invasive) 3. Non-metastatic disease 4. Radiotherapy after conservative surgery with irradiation of the breast alone and complement on the operating bed (optional) completed two to six months ago 5. Absence of postoperative complications 6. Early radio-induced epidermis grade ≥2 (CTCAE v4.0) persistent at inclusion 7. Chest circumference \<120 cm and Cup \<E, 8. Absence of breast reconstructive surgery, 9. Signature of informed consent, 10. Affiliation to a social security scheme for French patients. Group B 1. Patients over 18 years old, 2. Breast cancer (adenocarcinoma in situ or invasive) 3. Non-metastatic disease 4. Radiotherapy after conservative surgery with irradiation of the breast alone and complement on the operating bed (optional), completed two to six months ago 5. Absence of postoperative complications 6. Early grade 0-1 radiation-induced epidermis (CTCAE v4.0) at inclusion 7. Chest circumference \<120 cm and Cup \<E, 8. Absence of breast reconstructive surgery, 9. Signature of informed consent, 10. Affiliation to a social security scheme for French patients. Groups C, D Patients included in the SPLICIRAD study who have formulated their agreement for the use of supernumerary samples at the time of inclusion: * 10 patients with late pathologic radio-induced fibrosis (more than 6 months after the end of radiotherapy), grade CTCAE v4.0 ≥ 3 vs. * 10 patients without late pathological radio-induced fibrosis of grade CTCAE v4.0 ≤ 1 (follow-up after RT ≥4 years) Group E Patients over 18 who have given their consent to the Blood Establishment for the use of their samples for research purposes. Non-inclusion criteria for groups A, B, C, D: 1. Systemic inflammatory disease associated with individual radiosensitivity 2. Dermatological pathology in the breast 3. Radiotherapy having delivered an overdose\> 107% of the prescribed dose in at least 10% of the PTV 4. Diabetes 5. Active smoking 6. Chronic systemic anti-inflammatory therapy, immunotherapy, immunosuppressants, anti-TNF